Intervention: ASPIRIN
Trial phase: Phase 2
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: 325 mg aspirin po qd with arginine-restricted diet

Aspirin: 325 mg taken daily with an arginine-restricted diet
Eligibility criteria:
Inclusion Criteria:

Subjects must be 18-80 years of age with a history of surgically removed colon or rectal cancer, and have received treatment for their disease using drugs (adjuvant chemotherapy)
Subjects must have colon or rectal cancer with stage I, II, or III disease
Subjects should not have further treatment with radiation therapy. Subjects having already received adjuvant (i.e., post-operative) radiation therapy to the colon or rectum will be excluded. However, subjects receiving radiation therapy prior to surgery for rectal cancer are eligible for enrollment.
Subject's tumor must have been completely removed within the past 12 months, with first surveillance colonoscopy anticipated 12 weeks after study treatment start date (i.e. one-year after surgical removal).
Subjects must be in good physical status
If subjects are premenopausal and perimenopausal women, they must be using adequate birth control methods.
Subjects must have no history of another invasive cancer within 5 years
Subjects must have no further chemotherapy anticipated.
Subjects don't have special dietary requirements or additives. Subjects must not be consuming a diet that would preclude taking the study medication.
Subjects must have no concomitant use of calcium supplements (> 520mg/day).
Subjects must have no history of abnormal wound healing or repair, or conditions that predispose to the same.
Subjects don't have personal history of colon resection of or inflammatory bowel disease.
Subjects must give informed consent via consent form approved by the local Human Subjects Committee (Institutional Review Board).
If subjects are taking aspirin 81mg by mouth daily they will be eligible
Subjects must have no history of allergies or adverse reactions to aspirin.
Subjects don't have documented history of gastric/duodenal ulcer within the last 12 months.

Exclusion Criteria:

Subjects already received radiation therapy to the colon or rectum.
Subjects adhering to vegetarian diets.
Subjects are pregnant or lactating women.
Subjects are breastfeeding
Subjects are already taking aspirin 325mg by mouth daily.
Subjects are taking combination medication with more than 81mg aspirin.
Subjects are currently being treated for gastric/duodenal ulcer or experiencing symptoms at study entry.
Subjects have a history of any medical condition that would place them at risk as a result of a blood donation, they will be excluded from the study.
Subjects are taking blood-thinning drugs as warfarin (Coumadin)
Subjects are allergic to fenoprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium, naproxen, sulindac, tolmetin, or an orange food coloring known as tartrazine.
Subjects have liver damage or severe kidney failure